By: IPP Bureau
Last updated : November 21, 2025 9:56 am
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Global pharma powerhouse GSK and California-based biotech LTZ Therapeutics has announced a strategic research collaboration aimed at tackling some of the toughest cancers.
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy, combining GSK’s global reach with LTZ’s cutting-edge immunotherapy innovation.
The partnership targets up to four first-in-class therapies for both blood cancers and solid tumours, with GSK securing an exclusive worldwide option to license the resulting pre-clinical assets, according to the pharma giant.
MCEs represent a cutting-edge approach in immuno-oncology, harnessing the body’s own immune system to detect and destroy tumour cells. Unlike existing treatments, which often require hospital monitoring due to severe side effects, MCEs promise broad, sustained tumour targeting with a safer profile.
LTZ’s MCE platform has already shown encouraging results in preclinical studies across multiple cancer types.
Hesham Abdullah, Senior VP and Global Head of Oncology R&D at GSK, said: "This collaboration strengthens GSK’s commitment to next-generation cancer medicines. By combining our expertise with LTZ’s innovative platform, we aim to accelerate first-in-class MCE therapies that could transform outcomes while enabling broad access for patients."
Robert Li, Founder and CEO of LTZ, added: "Partnering with GSK marks a pivotal moment for LTZ. Together, we can advance myeloid biology to develop new treatment options for patients facing cancers with significant unmet need."
Under the agreement, LTZ receives a $50 million upfront payment and is eligible for preclinical, clinical, regulatory, and commercial milestone payments, along with tiered royalties on future global sales.